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Abstract
Background: Although the importance of work for patients with cancer is nowadays more acknowledged both in
the literature as well as in cancer survivorship care, effective interventions targeting the return to work of these
patients are still scarce. Therefore, we developed a nurse-led, stepped-care, e-health intervention aimed at
enhancing the return to work of patients with cancer. The objective of this study is to describe the content of the
intervention and the study design used to evaluate the feasibility and (cost) effectiveness of the intervention.
Methods: We designed a multi-centre randomised controlled trial with a follow-up of 12 months. Patients who
have paid employment at the time of diagnosis, are on sick leave and are between 18–62 years old will be eligible
to participate. After patients have signed the informed consent form and filled in the baseline questionnaire, they
are randomly allocated to either the nurse-led, stepped-care, e-health intervention called Cancer@Work, or care as
usual. The primary outcome is sustainable return to work. Secondary outcomes are sick leave days, work ability,
work functioning, quality of life, quality of working life and time from initial sick leave to full return to work without
extensive need for recovery. The feasibility of the Cancer@Work intervention and direct and indirect costs will be
determined. Outcomes will be assessed by questionnaires at 3, 6, 9 and 12 months of follow-up.
Discussion: The results of this study will provide new insights into the feasibility and (cost) effectiveness of
Cancer@Work, a nurse-led, stepped-care, e-health intervention for cancer patients aimed at enhancing their return
to work. If proven effective, the intention is to implement the Cancer@Work intervention in usual psycho-
oncological care.
Trial registration: NTR (Netherlands Trial Registry): NTR5190. Registered on 18 June 2015.
Keywords: Cancer survivors, Employment, Return to work, E-health, Psycho-oncological care, Study protocol,
Randomised controlled trial
Background
In the last decades, the survival rates of cancer have im-
proved significantly for most cancer types [1]. For that
reason, a growing number of cancer survivors of work-
ing age are now able to remain in or return to work.
However, a considerable number of patients with cancer
still experience difficulties getting back to work [2] or
they become unemployed [3] due to, for instance,
cancer-related side effects or an insensitive work envir-
onment [4]. It is important to diminish these adverse
work outcomes for patients with cancer, as work is both
a key aspect of cancer survivorship and is also associated
with higher levels of quality of life in these patients [5].
Although the importance of work for patients with
cancer is nowadays more acknowledged both in the lit-
erature as well as in cancer survivorship care, interven-
tions that are primarily aimed at enhancing return to
work of cancer patients are still scarce [6]. In the past
few years, a few studies reported results of an
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intervention primarily aimed at enhancing the return to
work of cancer patients [6–8]. These studies reveal that
it is feasible to deliver a work support intervention dur-
ing cancer care that is highly appreciated by patients [7,
9]. However, these work support interventions need im-
provement, as most did not show effectiveness on return
to work [9].
Most work support interventions for patients with
cancer have been delivered to all patients in the same
manner [6, 10]. Nevertheless, it is known that patients
widely differ both in the number and type of work-
related problems they experience upon their return to
work [11] as well as in the duration from initial sick
leave to sustainable return to work [12]. These differ-
ences indicate that a stepped-care intervention, in which
the intensity of the intervention is tailored to the pa-
tients’ needs, might be more effective and efficient. Such
a tailored intervention may lead to more effective
return-to-work outcomes.
Previous studies on cancer and work have taught us
three main things. First, self-assessed work ability is an
important prognostic factor for return to work, irre-
spective of clinical characteristics [7, 13]. This finding
has led to the hypothesis that return to work is influ-
enced by patients’ expectations and beliefs regarding re-
turn to work and that addressing misconception or
improving someone’s self-efficacy would enhance return
to work [13]. A successful approach to increase some-
one’s self-efficacy is the involvement of self-management
interventions [14] which might be based on cognitive
behavioural techniques [15] or problem-solving tech-
niques [15, 16]. Second, both employers and colleagues
as well as cancer care providers are important stake-
holders in the return to work of patients with cancer
[11]. It has appeared difficult to connect with the work-
place from the hospital [17], but a successful approach
to solve this problem might be the use of integrative-
care management [18]. Third, the longer the duration of
sick leave, the more difficult it is to return to work [19].
Addressing return to work in an early phase during can-
cer treatment might therefore be the window of oppor-
tunity. Moreover, two studies showed that cancer
patients appreciated receiving information on their re-
turn to work during early cancer treatment [8, 17]. For
these reasons, we choose to develop an early interven-
tion based on the theory of self-management and
integrative-care management.
Numerous studies have demonstrated that e-health is
a suitable way of delivering self-management interven-
tions for various conditions, including cancer [20, 21],
and to deal with various problems, including return to
work [22, 23]. In addition, e-health proved suitable for
delivering an integrative-care management intervention
as well [24]. Based on these findings, we choose to
deliver the intervention as an e-health intervention. We
define e-health as the process of providing the interven-
tion partly over the Internet including interaction with
health care providers.
Objective
The first objective of this paper is to describe the con-
tent of Cancer@Work, a nurse-led, stepped-care, e-
health intervention aimed at enhancing the return to
work of patients with cancer. The second objective is to
present the study design aimed at evaluating the Can-
cer@Work intervention in terms of feasibility and (cost)
effectiveness.
Method
Content of the Cancer@Work intervention
The Cancer@Work intervention has been developed
based on a non-systematic review on the use of and com-
pliance with e-health interventions, a non-systematic re-
view on cancer and work and on semi-structured
interviews with experts, cancer survivors, occupational
physicians and supervisors. Development of the nurse-led,
stepped-care, e-health intervention Cancer@Work has
been described extensively elsewhere [25].
The Cancer@Work intervention is an e-health inter-
vention blended with care from a specialised nurse of
the treating hospital or another care provider (e.g. social
worker), depending on the local setting. For readability
we will refer to this care provider as a specialised nurse.
The specialised nurse will (1) answer questions, (2)
monitor and supervise use of the Cancer@Work inter-
vention, (3) provide personal feedback on assignments of
the Cancer@Work intervention and (4) encourage pa-
tients to comply with the intervention. To be able to
blend their care with the Cancer@Work intervention,
specialised nurses have access to a special section of the
e-health intervention with which they are able to (1) see
whether patients have used the Cancer@Work interven-
tion, (2) see which functionalities each patient has used,
(3) evaluate the content of some of the assignments, (4)
answer questions from patients, (5) send messages to pa-
tients and (6) receive support from and answers to ques-
tions from an oncological occupational physician.
The intervention comprises two steps. Whether or not
the intervention goal was met with step 1 is measured
based on two indicators assessed by the specialised
nurse: (1) no return to work and/or (2) problems experi-
enced upon returning to work. If either indicator is
affirmative, patients will enter step 2.
Step 1: Information and advice in the Cancer@Work
intervention and integrative-care management
The focus of step 1 is to deliver patient-tailored informa-
tion on cancer and work with the help of the
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Cancer@Work intervention and to address misconcep-
tions on cancer and work. Functionalities of the Can-
cer@Work intervention include assignments to create
insight and to stimulate patients to take action on the
following topics: (1) possible financial consequences of
sick leave, (2) rights and obligations according to the
Dutch social security system when sick-listed (tailored to
the patient’s situation, i.e. a fixed versus temporary em-
ployment contract), (3) individual importance of work
and (4) return-to-work plan. Furthermore, the Cancer@-
Work intervention includes a library with background
information and a self-test to create awareness of the
abilities to return to work and to restructure cognitions.
The library includes, for instance, information on work
adjustments, social support and legal and insurance is-
sues, and it is conveniently arranged and has a search
function. Additionally, patients can learn from former
patients by means of advice, answers to frequently asked
questions and the documentary ‘Irrevocable’ on experi-
ences of cancer survivors upon returning to work. Pa-
tients are also able to keep a diary and to have a look at
assignments that they have previously made. Finally, the
Cancer@Work intervention offers patients the ability to
send private messages to their specialised nurse. Follow-
ing a patient’s first login, a welcome text and an instruc-
tion video explaining how to use the e-health
intervention will be available.
Integrative-care management implicates the involve-
ment of the patient’s supervisor, occupational physician
and general physician. To accomplish this, the patient
will be encouraged to invite his/her supervisor, occupa-
tional physician and/or general physician to use a public
website, specially developed as part of the e-health inter-
vention, containing information on cancer and work for
supervisors, occupational physicians and general physi-
cians (http://www.kanker-werk.nl/). When a patient in-
vites his supervisor, occupational physician and/or
general physician, they will receive an email with a short
explanation of the aim of the Cancer@Work interven-
tion. Once a patient has invited his supervisor, occupa-
tional physician or general physician, the Cancer@Work
intervention offers the ability to send private messages
to the stakeholder whom the patient has invited.
Step 2: Problem solving in extended Cancer@Work
intervention
The main functionality of the second step is a self-
management assignment based on the problem-solving
technique and blended care. Patients themselves actively
work on their problem with the aid of the Cancer@-
Work intervention and the additional support of their
specialised nurse. The ultimate goal is to create a strat-
egy to manage the patient’s problems that inhibit a suc-
cessful return to work. The self-management program is
split into three assignments. First, patients formulate
problems and opportunities regarding work. Second, pa-
tients formulate solutions for work-related problems.
Third, patients generate a plan to execute the chosen so-
lutions with regard to return to work. During this
process their specialised nurse will provide personalised
feedback after each assignment (online or face-to-face),
monitor and supervise the progress and encourage pa-
tients to comply with the intervention.
Conditions of use
There is no prescribed use of the Cancer@Work interven-
tion in terms of length, frequency or duration. Patients
themselves decide when to use the Cancer@Work inter-
vention and which content to use. They will go through
the Cancer@Work intervention at their own pace and
move from step 1 to step 2 if indicated. The Cancer@-
Work intervention will be available for 12 months.
Enhancing compliance
Every month a standardised email will be sent to patients
as a reminder of the functionalities of the Cancer@Work
intervention, if patients gave permission for these emails.
These reminders intend to increase compliance with the
intervention. Additionally, patients can ask their specia-
lised nurse for personal coaching at any time during avail-
ability of the Cancer@Work intervention.
Privacy and support for the Cancer@Work intervention
For technical questions only, patients are able to contact
the researcher by email. All patients are registered by
the researcher and receive a unique username and pass-
word (changeable later). Patients are able to log in to the
secured webpage by use of their unique username and
password; then verification by text message will take
place. The patient’s specialised nurse is able to view their
profile and provide personalised feedback.
Study design to evaluate the intervention Cancer@Work
For the description of the design of our evaluation study,
we used the items of the CONSORT statement [26] as
well as the SPIRIT checklist [27, 28] for improving the
quality of reporting randomised trials.
Organisation study
The design of this study is a non-blinded, multi-centre,
randomised controlled trial with a follow-up of 12 months.
An overview of consent, screening, enrolment, interven-
tion, timing of measurements and data collection is shown
in Fig. 1. The study will be conducted at the following
hospitals from various geographical regions in the
Netherlands: Academic Medical Center, Albert Schweitzer
Hospital, Reinier de Graaf Groep, Flevoziekenhuis, the
Antoni van Leeuwenhoek Hospital and Ter Gooi Hospital.
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The intervention group will receive the nurse-led,
stepped-care, e-health intervention Cancer@Work, and
the control group will receive care as usual, which is
standard psycho-oncological care. The medical ethics
committee of the Academic Medical Center approved the
study and the conduction of the study at all participation
hospitals. The board of management of the above-
mentioned participating hospitals advised positively about
local feasibility. Patients will sign an informed consent
form before participating.
Recruitment of study population
The treating physician or nurse will check each patient’s
eligibility at the outpatient clinic a few weeks after the
first cancer treatment, which consists in most cases of
surgery. The treating physician or nurse will inform all
eligible patients about the study and will ask for consent
to be contacted by the researcher. After telephonic
contact by the researcher, the researcher will include pa-
tients in the study if they are willing to participate and
after they have provided the signed informed consent
form. Thereafter, the patient will be randomised to
either the intervention group or to the control group.
Patients who meet the eligibility criteria but are not will-
ing to participate will be asked if they are willing to an-
swer a few questions by telephone about their work
situation at baseline and to answer by telephone a few
questions about their work situation at 12 months of
follow-up. We choose this strategy to be able to compre-
hend if a selective population of cancer patients have
participated in our evaluation study. The participant
flow diagram is shown in Fig. 2.
Participants
Eligible for this study will be patients with a primary
diagnosis of cancer who will be treated with curative in-
tent at the hospital of recruitment, between 18–62 years
old, in paid employment or self-employed and who have
sufficient knowledge of the Dutch language. Patients will
be excluded if they have a severe comorbidity or if they
have no Internet access.
Randomisation, blinding and treatment allocation
The researcher will perform randomisation by means of
the computerised randomisation program Alea [29]. By
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Fig. 1 Schedule of enrolment, intervention and assessments
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definite and allocation concealment is not possible. To
prevent unequal randomisation, randomisation will be
stratified by hospital department and age (cut-off value
50 years), since cancer diagnosis and higher age are im-
portant prognostic factors for delayed return to work
[30]. To equalise group sizes, blocks of 6 will be used.
Patients, care providers and the researcher will not be
blinded for group assignment.
Sample size
On average, we will include cancer patients at 6 weeks
or 42 days after diagnosis, and the follow-up time for
the primary outcome return to work will be 12 months
after inclusion, hence 12 months and 42 days after diag-
nosis. Earlier studies in our hospital showed that return
to work for patients with various cancer types was 64 %
at 12 months of follow-up from diagnosis [28]. In
addition, earlier studies in our hospital showed that re-
turn to work in the first 42 days is around 8 % [28].
Therefore, the return to work for the control group was
set at 64 % + 8 % = 72 %. In a study of Nieuwenhuijsen
et al. [29], an intervention group of 35 radiotherapy pa-
tients received a supportive work-related intervention in
a hospital. Time between diagnosis and the end of treat-
ment was a median 42 days. Return to work was mea-
sured between the end of treatment and work
resumption and was 89 % after 12 months. Therefore,
the return to work for the intervention group in our
intervention was also set at 89 %.
Based on our earlier studies on consecutive cancer pa-
tients, a power analysis indicated that we should include
a total of 170 patients with a follow-up of 1 year after
inclusion to indicate a difference of 89 % return to work
in the intervention group versus a 72 % return-to-work
rate in the control group, with a power of 80 % and p <
0.05. Accounting for 10 % loss to follow-up, 190 patients
should be included.
Contamination
Participants will be able to use any co-intervention they
wish. Since it is likely that other (vocational) rehabilita-
tion programs will have a significant effect on return to
work, participation in one of these co-interventions will
be monitored by means of follow-up questionnaires.
In theory, participants could provide knowledge about
the intervention and even access to Cancer@Work to
participants in the control group. However, as partici-
pants will be recruited individually via outpatient clinics
of hospitals and not, for instance, via support groups,
the chance that a patient from the intervention group
will know a patient from the control group is nil. None-
theless, we will ask participants in the control arm, via
follow-up questionnaires, whether they received any
support related to return to work.
Usual care in the Netherlands
Currently work-related issues are not structurally ad-
dressed as part of cancer (survivorship) care in the
Netherlands. However, it is becoming more common to
discuss this issue with a care provider at the hospital or
to receive support by a reintegration office specialised in
patients with cancer.
All sick-listed employees should have an occupational
physician who should legally advise them about return
Fig. 2 Participant flow diagram
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to work according to the blueprint of evidence-based
guidelines of the Dutch Association of Occupational
Physicians [31]. The Improved Gatekeepers Act covers
sick leave in the Netherlands and is in force during the
first 2 years of sick leave. The act states that a sick-listed
employee cannot be discharged and receives at least
70 % of his/her wage. The Improved Gatekeepers Act
states that employers and sick-listed employees are to-
gether responsible for work resumption, which means
that both parties can be sanctioned.
In the Netherlands, the social security system also
provides a safety net for sick-listed workers without an
employment contract according to the Improved Gate-
keepers Act. Application of the Act is the same, except
that these workers do not have an employer/workplace
to return to. Sick-listed workers without an employment
contract receive 70 % of their last daily wage during the
first 2 years of sick leave. The Dutch Social Security
Agency pays for the sick leave, is responsible for execut-
ing obligatory occupational health actions and should fa-
cilitate work resumption.
Self-employed persons can be privately insured against
sickness absence, but most are uninsured because of the
high costs. If a person is privately insured, it depends on
the insurance policy as to when someone receives a
supportive income, how much this supportive income is
and whether or not he/she receives sickness absence
counselling and vocational rehabilitation guidance.
Training specialised nurses to carry out the Cancer@Work
intervention
Specialised nurses will be educated on the work-related
issues of cancer patients, the social security system of
the Netherlands, how to coach patients with self-
management based on problem-solving techniques, how
to deliver personalised feedback and how to encourage
patients to comply with the Cancer@Work intervention
[32]. Training of the specialised nurses will consist of
two half-day training courses, supervised by an experi-
enced trainer and a member of the research team.
Assessment of the outcomes
Data will be both self-reported and collected by record-
ing use of the Cancer@Work intervention by partici-
pants and recording the content of the assignments
made by participants. The self-reported outcomes will
be assessed at baseline and at 3, 6, 9 and 12 months of
follow-up using questionnaires that will be completed by
participants randomised to the intervention group and
control group with online software. All participants will
receive an email with a link to complete the question-
naire online if they indicate to prefer questionnaires on-
line; otherwise, they will receive paper questionnaires.
Completing a questionnaire will take approximately
30 minutes.
Feasibility evaluation
The following feasibility outcomes will be measured ac-
cording to the Bowen scheme [33]: acceptability, demand,
practicality and compliance with the Cancer@Work inter-
vention. By acceptability we mean general usefulness of
the Cancer@Work intervention and of each functionality,
general user-friendliness of the Cancer@Work interven-
tion and of each functionality, appropriateness of the
intervention for the patient, satisfaction with support of
their specialised nurse in their use of the Cancer@Work
intervention, information that should be useful to add to
the Cancer@Work intervention, functionalities that
should be useful to add to the Cancer@Work intervention
and general ideas to improve the Cancer@Work interven-
tion. All these parameters will be measured at the patient
level with self-reported questionnaires at follow-up.
We define demand as the extent to which the
Cancer@Work intervention has actually been used and
include number of log-ins into the Cancer@Work inter-
vention, use of each functionality of the Cancer@Work
intervention (number) and the number and the content
of assignments. These will all be measured based on a
website monitoring program. To assess practicality we
will evaluate the self-perceived knowledge and skills of
the specialised nurse regarding the intervention, proto-
col for the specialised nurse, website for the specialised
nurse and appropriateness of the training and prepar-
ation of the specialised nurse. These will all be assessed
as part of the semi-structured interview with the specia-
lised nurse at the end of the study.
Compliance by patients will be measured with a web-
site monitoring program. Reasons for non-compliance
will be measured based on self-reported questionnaires
at follow-up as well as on whether or not use of the
Cancer@Work intervention fits in the patient’s daily
routine, since that is often a reason for not complying.
Effect evaluation
The primary outcome of sustainable return to work is
measured as any return to work (yes/no) at follow-up in-
dependent to the number of contract hours which is
sustained for at least 4 consecutive weeks without recur-
rent sick leave. Return to work is either partial return to
work (working a part of contract hours) or full return to
work (working all contract hours).
The secondary outcomes are full return to work (yes/
no) at follow-up defined as working the hours stated in
the work contract, time to any (either partial or full) re-
turn to work in days from the first day of sick leave to
the date of any return to work and time to return to
work in days from the first day of sick leave to the date
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of full return to work. These return-to-work measures
must be sustained for at least 4 consecutive weeks. Fur-
thermore, secondary outcome measures are work ability
using the first three questions of the Work Ability Index
(WAI) [34], work functioning using the Work Limita-
tions Questionnaire (WLQ) [35, 36], quality of life using
the SF-12 [37], quality of work life using the QWLQ-CS
(De Jong et al. in preparation) [38] and the time from
initial sick leave to full return to work without extensive
need for recovery using a subscale of the ‘perception and
assessment of work questionnaire’ (VBBA) [39].
Prognostic and descriptive characteristics
Prognostic characteristics are age, gender, marital status
(married, single, widowed, divorced), bread winner status
(yes, no, shared), education (7 categories), cancer diagnosis,
treatment type (surgery, radiotherapy, chemotherapy, hor-
monal therapy, other), time since diagnosis (in months),
treatment duration and comorbidity (13 diseases). Work-
related factors include characteristics of the job (working
hours per week, job position, company size, shift work (no,
yes with/without night shifts), type of contract (permanent,
temporary, self-employed), years in present position, years
of work experience, and work adjustments), work demands
(VBBA) [39], importance of work (0 (not important)–100
(most important)), current problems with work (yes/no),
need for information or support regarding work-related
problems (1 (no)–5 (very much)) and expectations regard-
ing return to work in next 4 weeks (1 (definitely yes)–4
(probably not)). Fatigue is measured with the 20-item
Multidimensional Fatigue Inventory (MFI) [40] with higher
scores indicating more fatigue, depression is measured with
the 20-item CES-D [41] with higher scores indicating more
depressive symptoms and cognitive functioning at work is
measured with the 20-item Cognitive Symptom Checklist-
Work questionnaire [42]. The following descriptive charac-
teristics will be measured: income (in euros per month) and
work participation status at follow-up (employed, un-
employed, disability pension, retired).
Economic evaluation
The economic evaluation will be conducted from a soci-
etal perspective. The following direct costs will be mea-
sured for both groups: costs to deliver the Cancer@Work
intervention or costs to deliver care as usual and the fol-
lowing indirect costs: absenteeism, lost work productivity,
lost earnings and work adjustments. The direct costs will
be determined by means of the costs to deliver the
Cancer@Work intervention (i.e. costs to develop and
maintain the e-health intervention, average specialised
nurse wage, the amount of time spent on each participant
and training costs) or costs to deliver care as usual (i.e.
average specialised nurse wage and the amount of time
spent on addressing return to work of each participant).
Absenteeism costs will be determined by means of total
days on sick leave from the first day of sick leave until
follow-up and on income and work productivity costs by
the WLQ and on income [35, 36]. Additionally, lost earn-
ings will be determined on the basis of the differences be-
tween income at baseline and income at follow-up. Work
adjustments will be assessed by means of the cost of each
work adjustment.
Direct costs will be acquired by the specialised nurses
keeping track of the time spent on each participant and
by the research team on keeping track of the costs to de-
velop and maintain the Cancer@Work intervention and
training costs to train specialised nurses to deliver the
Cancer@Work intervention. Indirect costs will be ac-
quired by a self-reported questionnaire completed by
participants during follow-up.
Intermediate effect of the Cancer@Work intervention on
self-management and work-related self-efficacy
The Cancer@Work intervention is a self-management
intervention based on problem-solving techniques and
cognitive behavioural techniques. The key mechanisms
of the Cancer@Work intervention are therefore self-
management skills and work-related self-efficacy. To
measure this change in self-management skills, we will
measure perceived confidence in own self-management
skills on a visual analogue scale of 0 (no confidence) to
100 (high confidence). Work-related self-efficacy will be
measured with the 11-item questionnaire ‘expectations
regarding work functioning’ [43] with higher scores indi-
cating more self-efficacy regarding work.
Statistical analysis
All analyses will be based on the intention-to-treat (ITT)
principle. All baseline data and data regarding primary
and secondary outcomes as well as data from the feasi-
bility evaluation will be presented using descriptive sta-
tistics. Differences in baseline data between the
intervention and control group will be assessed using
Student’s t test for continuous data and the chi-squared
test for categorical data.
Feasibility evaluation
The following feasibility outcomes will be described accord-
ing to the Bowen scheme [33]: acceptability, demand,
practicality and compliance with the Cancer@Work inter-
vention. The following baseline parameters will be analysed
to verify whether they are related to non-compliance: treat-
ment type, treatment duration, age, education, gender, need
for cognition regarding return to work, need for support
with return to work, existence of problems with work, ex-
pectations concerning return to work, expectations con-
cerning the Cancer@Work intervention, Internet skills and
self-management skills. The following parameters measured
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at follow-up on patient level by means of self-reported
questionnaires will be related to non-compliance: whether
or not their expectations about the Cancer@Work inter-
vention are fulfilled, work situation at follow-up and satis-
faction with the Cancer@Work intervention.
Effectiveness
The relative risk and 95 % confidence interval for
returning to work at 12 months of follow-up will be cal-
culated for the intervention group versus the control
group. In addition to this ITT analysis aimed at ’all-cause
return to work’, the analysis will be performed excluding
those patients who have died during follow-up and those
who have a life expectancy of less than a few months,
because they will not return to work.
To assess whether the Cancer@Work intervention is
more effective for those who need it most, a planned sub-
group analysis for patients with a high risk of not return-
ing to work will be performed. This subgroup will be
identified based on having physical heavy work, low work
ability at baseline, high levels of fatigue, depression and
cognitive problems at work at 3 and 6 months of follow-
up and a long duration of cancer treatment [13, 30]. In
addition, to ascertain whether the Cancer@Work inter-
vention is more effective for various subgroups of patients
who are more or less prone to benefit from self-
management, a subgroup analysis will be done for young
versus old, male versus female and lower education level
versus higher education level [44].
Effectiveness secondary parameters
The number of days until participants’ return to work
(either full or partial) assessed at 12 months will be ana-
lysed using the Kaplan-Meier survival method, and
differences between groups will be tested with the
log-rank test. Patients who dropped out of the study
will be censored. If statistically significant differences
in prognostic characteristics between the intervention
and the control group are found at baseline, a Cox
regression analysis will be performed including those
prognostic parameters.
A longitudinal multilevel analysis will be used to
examine differences between intervention and the con-
trol group with regard to improvement of work ability,
work limitations, quality of work life and quality of life.
A cut-off score of ≥6 on the subscale need for recovery
of the VBBA will be used to divide the group of partici-
pants who returned to work without extensive need for re-
covery versus the group of participants who returned to
work with an extensive need for recovery plus the partici-
pants who did not return to work. The number of days
until participants’ return to work without extensive need
for recovery at 12 months will be analysed using the
Kaplan-Meier survival method, and differences between
groups will be tested with the log-rank test. If statistically
significant differences in prognostic characteristics be-
tween the intervention and the control group are found at
baseline, a Cox regression analysis will be performed in-
cluding those prognostic parameters.
Economic evaluation
Direct and indirect costs will be summed for each par-
ticipant. Using bootstrapping, mean differences in direct,
indirect and total costs will be calculated between the
control group and the intervention group [45]. Incre-
mental cost-effectiveness ratios will be calculated by
assessing the ratio between the differences in costs be-
tween the intervention and control group to the differ-
ences in return-to-work rates between the groups.
Intermediate effect of the Cancer@Work intervention on
self-management skills and work-related self-efficacy
A longitudinal multilevel analysis will be used to exam-
ine differences between the intervention and the control
group on self-management skills and work-related self-
efficacy.
Discussion
The objective of this study is to describe the content of
the nurse-led, stepped-care, e-health intervention Can-
cer@Work and to explain the study design used to
evaluate the feasibility and (cost) effectiveness of this
intervention.
As far as we are aware, this is the first e-health inter-
vention especially developed for patients with cancer
aimed at enhancing their return to work. Furthermore, a
stepped-care intervention for supporting return to work
is innovative as well. The Cancer@Work intervention
provides an easily accessible intervention to deal at an
early stage with work-related problems that might arise.
When it is evident that return to work is hampered, this
stepped-care intervention provides more intense problem-
solving support. Additionally, the Cancer@Work int-
ervention might bridge the gap between primary care and
occupational health care, which is important, as both
stakeholders are important for a return to work. The re-
sults of this study will provide new insights into the feasi-
bility and effectiveness of a stepped-care approach and an
e-health intervention for cancer patients aimed at enhan-
cing their return to work.
Compliance is one of the main difficulties of an e-
health intervention. Duffecy et al. tackled this problem
successfully by means of supportive accountability [46].
This method involves a group start of the e-health inter-
vention; patients could buzz each other when they did
not log in for a certain amount of time. Unfortunately,
our e-health intervention is not suitable for supportive
accountability, as it cannot be used with a group start;
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return-to-work trajectories differ widely among patients,
and our e-health intervention is not a fixed program.
However, we tried to minimize the risk of low compliance
by combining the e-health intervention with face-to-face
contact, so-called blended care, by sending reminders to
patients, by tailoring information to the patient (i.e. fixed
versus temporary employment contract) and by involving
all end users in the development of the intervention [47].
Internet illiteracy is associated with a lower education
level, while research indicates that self-management in-
terventions might be more effective for patients with a
lower educational level [44]. For that reason, we have
spent extra time and effort in the development of the
Cancer@Work intervention component to ensure that it
was very easy to use. Moreover, one of the functionalities
of the Cancer@Work intervention component is the
ability for patients to contact their specialised nurse or
the researcher at any time during weekdays when they
have problems with the content or technical problems.
The strengths of our study design are the inclusion of
patients from various hospitals from various geo-
graphical regions in the Netherlands, implementing the
Cancer@Work intervention into usual care without
much deviation from usual care and the follow-up of
patients unwilling to participate in the trial but willing
to fill in baseline and follow-up questionnaires.
A limitation of our study design is the inability of
blinding patients and specialised nurses to the outcome
of the randomisation. This might cause contamination
between groups. Alternatives of randomisation on a pa-
tient level are cluster randomisation or a step-wedge de-
sign. A difficulty of cluster randomisation is the need for
comparable clusters [48], which is not possible for this
study on the hospital level as patient characteristics
differ between hospitals. Likewise, a difficulty of a step-
wedge design is the need for a larger sample size, start-
ing with all clusters (i.e. hospitals) at the same time and
an equal distribution of patients between clusters, which
is burdening and results in complex statistical analyses
[49]. For these reasons we believe that randomisation on
the patient level is the best option for this study. More-
over, although specialised nurses might alter their usual
care due to participation in the study, patients allocated
to the control group do not have access to the Cancer@-
Work intervention.
If proven effective, the Cancer@Work intervention will
be implemented in usual care. The e-health intervention
might also be incorporated as a work-module into
broader psychosocial e-health interventions for patients
with cancer.
Trial status
The study is currently recruiting patients. Inclusion
started on 1 September 2015.
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